
-
Aldeyra Therapeutics Inc. NasdaqCM:ALDX Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Location: 131 Hartwell Avenue, Lexington, MA, 02421, United States | Website: https://www.aldeyra.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
62.07M
Cash
90.06M
Avg Qtr Burn
-11.43M
Short % of Float
9.97%
Insider Ownership
3.13%
Institutional Own.
56.36%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Reproxalap (ADX-102) Details Dry eye syndrome | NDA Resubmission | |
Reproxalap (ADX-102) Details Rare genetic disease, Rare diseases, Allergic conjunctivitis | Phase 3 Update | |
ADX-2191 Details Eye disease , Retinitis Pigmentosa | Phase 2/3 Initiation | |
Phase 2 Data readout | ||
ADX-629 Details Sjögren-Larsson Syndrome | Phase 2 Data readout | |
ADX-629 Details Atopic dermatitis | Phase 2a Update | |
ADX-246 Details Atopic dermatitis, Skin disease/disorder | Phase 1/2 Data readout | |
ADX-248 Details Age-related macular degeneration, Geographic atrophy | Phase 1/2 Initiation | |
ADX-248 Details Atopic dermatitis, Skin disease/disorder | Phase 1 Initiation | |
ADX-743 Details Metabolic disorder, Obesity | IND Submission | |
ADX-631 Details Eye disease , Geographic atrophy | IND Submission | |
ADX-629 Details Idiopathic Nephrotic Syndrome | Failed Discontinued | |
ADX-629 Details Chronic cough | Failed Discontinued | |
ADX-2191 Details Eye disease , Proliferative vitreoretinopathy, Rare diseases, Primary Vitreoretinal Lymphoma | Failed Discontinued |